Abstract B184: HSP90 inhibitor STA-9090 potently suppresses heterogeneous KIT kinase-domain mutations responsible for gastrointestinal stromal tumor progression during imatinib therapy
Jonathan A. Fletcher(Harvard University), George D. Demetri(Dana-Farber Cancer Institute), Rachel Donsky(Brigham and Women's Hospital), Kevin P. Foley(Unknown), Stephen Swank(Brigham and Women's Hospital), Bernadette Liegl(Brigham and Women's Hospital), Jennifer E. Morgan(Great Ormond Street Hospital), Christopher D.�M. Fletcher(Brigham and Women's Hospital), Chandrajit P. Raut(Dana-Farber Cancer Institute), Tanya A. Rege(Brigham and Women's Hospital), Michael C. Heinrich(VA Portland Health Care System), Yuexiang Wang(Shanghai Institute of Nutrition and Health), Wen‐Bin Ou(Zhejiang Sci-Tech University), Christopher C. Corless(Oregon Health & Science University), Maria Dêbiec‐Rychter(Center for Human Genetics)
Cited by 3
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
|Journal of the National Comprehensive Cancer Network|2010|1.2k
High-throughput oncogene mutation profiling in human cancer
|Nature Genetics|2007|996